These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28869418)

  • 1. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
    Higashiguchi M; Matsumoto T; Fujii T
    Antivir Ther; 2018; 23(2):157-165. PubMed ID: 28869418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase inhibitors for preventing and treating influenza in children.
    Wang K; Shun-Shin M; Gill P; Perera R; Harnden A
    Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).
    Wang K; Shun-Shin M; Gill P; Perera R; Harnden A
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD002744. PubMed ID: 22513907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
    Kashiwagi S; Watanabe A; Ikematsu H; Uemori M; Awamura S;
    Clin Infect Dis; 2016 Aug; 63(3):330-7. PubMed ID: 27118785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.
    Kashiwagi S; Watanabe A; Ikematsu H; Awamura S; Okamoto T; Uemori M; Ishida K
    J Infect Chemother; 2013 Aug; 19(4):740-9. PubMed ID: 23732307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.
    Watanabe A
    J Infect Chemother; 2013 Feb; 19(1):89-97. PubMed ID: 22907567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
    Watanabe A; Chang SC; Kim MJ; Chu DW; Ohashi Y;
    Clin Infect Dis; 2010 Nov; 51(10):1167-75. PubMed ID: 20936975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2017 Sep; 23(9):627-633. PubMed ID: 28709902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
    Ishiguro N; Koseki N; Kaiho M; Ariga T; Kikuta H; Oba K; Togashi T; Morita K; Inagawa A; Okamura A; Yamazaki S; Shida S; Konno M; Kawamura N; Ishizaka A; Takada K; Tsubakihara K; Nagano N; Shibata M; Furuyama H; Matsuzono Y; Koike A; Murashita M; Hatae Y; Arioka H; Yamanaka T; Watanabe T; Tabata Y; Kumita Y; Hazama K; Akutsu Y; Aoyagi H; Tobise C; Azuma K; Yasoshima K; Sawada Y; Uetsuji K; Tsuchida A; Tsuchiyama A; Yasuda K; Odagawa Y; Yoshioka M
    J Infect Chemother; 2018 Jun; 24(6):449-457. PubMed ID: 29487035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children.
    Nakano T; Ishiwada N; Sumitani T; Uemori M; Isobe K;
    Pediatrics; 2016 Dec; 138(6):. PubMed ID: 27940664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
    Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M
    Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):81-5. PubMed ID: 24486167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.
    Zhao Y; Gao Y; Guyatt G; Uyeki TM; Liu P; Liu M; Shen Y; Chen X; Luo S; Li X; Huang R; Hao Q
    Lancet; 2024 Aug; 404(10454):764-772. PubMed ID: 39181596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2016 Sep; 22(9):605-10. PubMed ID: 27493024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Nov; 21(11):802-7. PubMed ID: 26410550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S; Ishikawa Y; Yamaguchi H; Shiosakai K
    J Infect Chemother; 2018 Sep; 24(9):718-724. PubMed ID: 29861186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.
    Koseki N; Kaiho M; Kikuta H; Oba K; Togashi T; Ariga T; Ishiguro N
    Influenza Other Respir Viruses; 2014 Mar; 8(2):151-8. PubMed ID: 23953886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.